Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system
Haemophilia
.
2022 Sep;28(5):e145-e148.
doi: 10.1111/hae.14632.
Epub 2022 Jul 27.
Authors
Donald C Moore
1
,
Joseph B Elmes
2
,
Justin R Arnall
3
,
Scott A Strassels
4
,
Jai N Patel
5
Affiliations
1
Atrium Health, Department of Pharmacy, Levine Cancer Institute, Charlotte, North Carolina, USA.
2
Atrium Health, Department of Pharmacy, Levine Cancer Institute, Concord, North Carolina, USA.
3
Atrium Health, Specialty Pharmacy Service, Charlotte, North Carolina, USA.
4
Department of Pharmacy, Atrium Health, Charlotte, North Carolina, USA.
5
Atrium Health, Department of Cancer Pharmacology and Pharmacogenomics, Levine Cancer Institute, Charlotte, North Carolina, USA.
PMID:
35895993
DOI:
10.1111/hae.14632
No abstract available
Publication types
Letter
MeSH terms
Databases, Factual
Hemophilia A* / drug therapy
Humans
Immune Checkpoint Inhibitors
Pharmacovigilance*
United States
United States Food and Drug Administration
Substances
Immune Checkpoint Inhibitors